Hologic, Inc. (NASDAQ:HOLX) Shares Sold by National Bank of Canada FI

Key Points

• National Bank of Canada FI reduced its stake in Hologic, Inc. by 3.8% during the first quarter, retaining 250,165 shares valued at approximately $15.45 million.
• Hologic recently reported earnings of $1.08 per share, surpassing analysts' expectations, with a quarterly revenue of $1.02 billion, a 1.2% increase year-over-year.
• The stock has seen mixed ratings from analysts, with a consensus rating of “Moderate Buy” and an average target price of $77.83.

National Bank of Canada FI reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,165 shares of the medical equipment provider's stock after selling 9,837 shares during the quarter. National Bank of Canada FI owned 0.11% of Hologic worth $15,452,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Allworth Financial LP grew its stake in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Hologic during the first quarter worth approximately $42,000. Larson Financial Group LLC grew its stake in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after buying an additional 722 shares during the period. Raiffeisen Bank International AG purchased a new stake in Hologic during the fourth quarter worth approximately $49,000. Finally, West Financial Advisors LLC purchased a new stake in Hologic during the first quarter worth approximately $50,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and boosted their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Evercore ISI boosted their target price on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Raymond James Financial reissued an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $77.83.

Hologic Stock Up 1.5%

HOLX traded up $1.03 during trading on Wednesday, hitting $68.98. The company had a trading volume of 1,746,581 shares, compared to its average volume of 1,708,530. The company has a market cap of $15.34 billion, a PE ratio of 28.62, a P/E/G ratio of 2.47 and a beta of 0.49. The business has a 50-day moving average of $65.43 and a 200-day moving average of $62.69. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.06 earnings per share. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.